Zylox-Tonbridge Medical Technology Co., Ltd. Class H (818 – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Alexis Yan from Morgan Stanley maintained a Buy rating on the stock and has a HK$18.60 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alexis Yan has given his Buy rating due to a combination of factors including the positive adjustments made to the earnings per share forecasts for Zylox-Tonbridge Medical Technology Co., Ltd. Class H. The projections for 2025, 2026, and 2027 show significant increases of 14.8%, 13.6%, and 12.4% respectively, driven by a decrease in operating expenses that offsets the lower sales forecasts.
Furthermore, the company is expected to achieve impressive sales growth of 35% in 2025 and 30% in 2026, alongside a net profit growth exceeding 40% per annum, aligning with the management’s guidance. Consequently, the price target for the stock has been raised to HK$18.6, reflecting the optimistic outlook and potential for substantial returns.
According to TipRanks, Yan is an analyst with an average return of -9.1% and a 33.33% success rate.